LEADER 01797cas--2200529---4500 001 990000333590203316 005 20110207142519.0 011 $a0001-4842 035 $a0033359 035 $aUSA010033359 035 $a(ALEPH)000033359USA01 035 $a0033359 100 $a20010202d1968----km-y0ENGy0103----ba 101 $aeng 102 $aUS 110 $aafazz--|||| 200 1 $aAccounts of chemical research$fAmerican Chemical Society 207 1$aA.1, n.1(1968)- 210 $aWashington$cAmerican Chemical Society$d1968- 215 $av.$cill.$d29 cm 326 $aMensile 606 0 $aChimica$xPeriodici$2BNCF 676 $a540.5 712 02$aAmerican Chemical Society 801 0$aIT$bsalbc$gISBD 856 4 $uhttp://pubs.acs.org/journal/achre4$4.$zOnline da workstation autorizzate 912 $a990000333590203316 958 $aSCI$bPER I$c1968-2009;$l1981; 959 $aSE 979 $aPATTY$b90$c20010202$lUSA01$h1405 979 $c20020403$lUSA01$h1641 979 $aPATRY$b90$c20040406$lUSA01$h1623 979 $aANGELA$b90$c20110107$lUSA01$h1613 979 $aANGELA$b90$c20110107$lUSA01$h1614 979 $aANGELA$b90$c20110110$lUSA01$h1213 979 $aCIANATIEMP$b90$c20110111$lUSA01$h0935 979 $aCIANATIEMP$b90$c20110111$lUSA01$h0936 979 $aCIANATIEMP$b90$c20110111$lUSA01$h0941 979 $aCIANATIEMP$b90$c20110111$lUSA01$h0942 979 $aCIANATIEMP$b90$c20110111$lUSA01$h0943 979 $aCIANATIEMP$b90$c20110111$lUSA01$h0943 979 $aCIANATIEMP$b90$c20110112$lUSA01$h1017 979 $aCIANATIEMP$b90$c20110126$lUSA01$h1224 979 $aCIANATIEMP$b90$c20110126$lUSA01$h1629 979 $aCIANATIEMP$b90$c20110207$lUSA01$h1425 996 $aAccounts of chemical research$9265237 997 $aUNISA LEADER 01328nam 2200337z- 450 001 9910689849003321 005 20161209104829.0 035 $a(CKB)5860000000021891 035 $a(BIP)012599231 035 $a(EXLCZ)995860000000021891 100 $a20220406c2004uuuu -u- - 101 0 $aeng 200 10$aEncouraging small business growth and access to capital $ehearing before the Subcommittee on Oversight and Investigations of the Committee on Financial Services, U.S. House of Representatives, One Hundred Eighth Congress, second session, September 23, 2004 215 $a1 online resource (v, 61 p.) 311 $a0-16-074368-0 517 $aEncouraging small business growth and access to capital 606 $aSmall business$zUnited States$xFinance 606 $aSmall business$zUnited States$xGrowth 606 $aVenture capital$zUnited States 606 $aSmall business$xGovernment policy$zUnited States 610 $aSmall business 610 $aVenture capital 610 $aBusiness & economics 615 0$aSmall business$xFinance. 615 0$aSmall business$xGrowth. 615 0$aVenture capital 615 0$aSmall business$xGovernment policy 906 $aBOOK 912 $a9910689849003321 996 $aEncouraging small business growth and access to capital$93135923 997 $aUNINA LEADER 04942nam 2201345z- 450 001 9910557666403321 005 20220111 035 $a(CKB)5400000000044842 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76871 035 $a(oapen)doab76871 035 $a(EXLCZ)995400000000044842 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aDrug-Drug Interactions 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (242 p.) 311 08$a3-0365-2035-X 311 08$a3-0365-2036-8 330 $aDrug-drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb-drug or food-drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions. 606 $aBiology, life sciences$2bicssc 606 $aResearch & information: general$2bicssc 610 $a(?)-sophoranone 610 $a1A2 610 $a2B6 610 $a2C19 610 $a2C8 610 $a2C9 610 $a2D6 610 $a3A4 610 $aADME 610 $aadverse drug reactions 610 $abiflavonoid 610 $achronic kidney disease 610 $acompetitive inhibition 610 $acomputational prediction 610 $aCYP 610 $aCYP1A1 610 $aCYP1A2 610 $aCYP2C9 610 $aCYP2D6 610 $aCYP3A 610 $aCYP3A4 610 $acytochrome P450 610 $acytochromes P450 610 $aDDI 610 $aDexamethasone 610 $adrug interaction 610 $adrug interactions 610 $adrug metabolism 610 $adrug transporter 610 $adrug-drug interaction 610 $adrug-drug interaction 610 $adrug-drug interactions 610 $adrug-drug interactions 610 $aexpression 610 $afexofenadine 610 $agepants 610 $ahigh plasma protein binding 610 $ain silico 610 $ain vitro 610 $ain vivo 610 $ainhibitor 610 $aixazomib 610 $aKetoconazole 610 $alasmiditan 610 $aLexicomp 610 $alow permeability 610 $aLoxoprofen 610 $amechanism-based inhibition 610 $ametabolic DDI 610 $ametabolism 610 $amigraine 610 $amonoclonal antibodies 610 $anon-competitive inhibition 610 $aO-desmethyltramadol 610 $aOATP1B1 610 $aOATP1B3 610 $aorganic anion transporting polypeptide 1A2 (OATP1A2) 610 $aP-glycoprotein (P-gp) 610 $aP450 610 $apharmacokinetics 610 $aphysiologically-based pharmacokinetics 610 $aplasma concentration 610 $apolypharmacy 610 $apotent inhibition 610 $aQSAR 610 $aregulation 610 $aRumex acetosa 610 $aselamariscina A 610 $asignal detection algorithms 610 $aspontaneous reporting systems 610 $asubset analysis 610 $asubstrate 610 $asystemic exposure 610 $atadalafil 610 $aticagrelor 610 $atissue-specific 610 $atramadol 610 $atyrosine kinase inhibitors 610 $aubiquitination 610 $auridine 5'-diphosphoglucuronosyl transferase 615 7$aBiology, life sciences 615 7$aResearch & information: general 700 $aKim$b Dong Hyun$4edt$01304704 702 $aLee$b Sangkyu$4edt 702 $aKim$b Dong Hyun$4oth 702 $aLee$b Sangkyu$4oth 906 $aBOOK 912 $a9910557666403321 996 $aDrug-Drug Interactions$93027633 997 $aUNINA